Objective Intensive Care Units (ICUs), where critically ill patients are cared for by specialized care providers, paradoxically representa life-threatening environment for 100% of patients: while ICU stay usually lasts <1 week, 90% of ICU survivors showcatastrophic, long-term consequences. This happens because dangerous complications are often addressed too late,leading to increased mortality risk. In addition, noise and light levels in Intensive Care Units are too high and induce sleepdeprivation: a condition that often leads to delirium. Clinical evidence shows that ICU-acquired co-morbidities should be prevented and addressed by a multi-disciplinary team made of clinicians, families, nurses, therapists. The goal is to deliver seamless patient of care from the first hour in the ICU, up to the discharge in the ward and then at home. Current clinical practice, though, is not able, alone, to deliver an effective and scalable continuum of care. Thanks to years of research and clinical trials, Cognuse developed an IT platform capable of disrupting the patients’ carewith comprehensive interfaces for everyone in the care loop. By providing each ICU bed with one tablet, patients, cliniciansand families are empowered. The detection of complications is made quick and effective; an automatized system allows tomonitor and reduce environmental stressors; families are involved in the care loop and informed; patients themselves aresupported and challenged in exercising to recover better. After testing their solution in USA, the Estonian Company Cognuseaims at disrupting now the critical care in Europe. During Phase 1 project the Company will assess software expansion and scale-up plan, will conduct clinical trials forvalidation and software certification and will establish a sound go-to- market strategy to ensure a swift market uptake of theproposed solution. Fields of science natural sciencescomputer and information sciencessoftwaresocial sciencessociologydemographymortalitymedical and health sciencesclinical medicinephysiotherapymedical and health sciencesclinical medicinecritical care medicine Programme(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-1-2016-2017 Funding Scheme SME-1 - SME instrument phase 1 Coordinator OU COGNUSE Net EU contribution € 50 000,00 Address Telliskivi tn 60a 10412 Tallinn Estonia See on map Region Eesti Eesti Põhja-Eesti Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
